helps in the recovery of lipopolysaccharide-fed mice with mild intestinal dysfunction.

BACKGROUND

Mild intestinal dysfunction, linked to subtle yet significant health issues, can be induced by lipopolysaccharide (LPS), a Gram-negative bacterial component that disrupts gut function and triggers inflammation. has shown promise as a probiotic for gut health due to its roles in mucin degradation and short-chain fatty acid production. This study explores the therapeutic effects of on LPS-induced mild intestinal dysfunction in mice.

METHODS

Thirty-eight 6-week-old C57BL/6 mice were split into control ( = 19) and LPS-treated ( = 19) groups. LPS-treated mice received 300 μg/kg/day of LPS for 4 weeks, followed by supplementation at 41 mg/kg/day (Akk1) or 82 mg/kg/day (Akk2) for another 4 weeks. Gut microbiota was analyzed via metagenomic sequencing, and gene expression was evaluated through transcriptomics.

RESULTS

LPS significantly altered gut microbiota, reducing diversity and increasing pathogenic genera like Lachnoclostridium. supplementation, particularly at higher doses, partially restored gut microbiota by increasing beneficial genera such as Muribaculum. Transcriptomics showed that LPS induced immune and inflammatory responses, while reduced these effects by modulating pathways like TNF and NF-kappa B signaling.

CONCLUSION

mitigates LPS-induced gut dysfunction by restoring microbiota balance and modulating immune responses, highlighting its potential as a therapeutic agent for gut health.